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Accepted 5 January 2012Fertility preservation is crucial for women experiencing
diminished ovarian reserve (DOR) due to disease treatments or
aging. From preserving ovarian tissues to oocytes, scientists
are trying to find more convenient, cost-effective ways to meet
women’s fertility needs. Since the first successful live birth
from a human frozen/thawed oocyte in 1986 [1], more
researchers have devoted themselves to this field, developing
techniques and applications for oocyte cryopreservation.
Progress in human oocyte cryopreservation, especially vitri-
fication along with its obstetric outcome, has been one of the
major issues in reproductive medicine recently. Chen et al [2]
reported a 75% survival rate, 67% fertilization rate, and 33%
pregnancy rate following a new oocyte slow freezing/thawing
procedure. Vitrification is thought to be a highly efficient
technique for embryo and oocyte cryopreservation [3e5]. The
vitrification of oocytes allows higher postwarm survival rates
than slow freezing. However, significant improvements have
been achieved in both cryopreservation methods [2,6].
Several research studies on the outcome of oocyte cryo-
preservation have been published. Kim et al [7] reported that
in fertile women, vitrification of oocytes produces pregnancy
and implantation rates comparable to those of frozen embryos.
Although the data were limited, a systematic review of cry-
opreserved oocytes showed no obvious association with
adverse pregnancy outcome [8]. A multicenter, prospective
clinical trial to evaluate the efficacy, safety, and outcome of
human oocyte cryopreservation is currently ongoing [9].
However, there is still a need for more supportive evidence of
oocyte vitrification.
Studies in this field have mainly focused on young or fertile
women needing cryopreservation for medication purposes
[7,10e14], but rarely has there been concern about women
who are at an advanced maternal age or infertile [15,16].
Because oocyte number and quality begin to decline from age* Corresponding author. 1F, No. 12, Dongmen St., Hsinchu City 300,
Taiwan.
E-mail address: stork.lai@msa.hinet.net (H.-H. Lai).
1028-4559/$ - see front matter Copyright  2012, Taiwan Association of Obstetri
http://dx.doi.org/10.1016/j.tjog.2012.09.02535 years onward, it is necessary to evaluate the possibility of
“self-cryobanking” for women with DOR who could then
conceive using their own donor eggs. From the oocyte banking
point of view, the greater the number of oocytes collected, the
better the chances of ensuring offspring. Therefore, we have
proposed a strategy whereby we perform multiple oocyte
retrievalevitrification cycles to accumulate a sufficient
number of oocytes for such patients.
A 39-year-old single woman came to our clinic in March
2009 asking for fertility preservation. Despite poor ovarian
function, she did not want to give up her chance of becoming
pregnant with her own biological child. After a detailed
consultation on the treatment process and under a full consent
agreement, she decided to vitrify her oocytes.
In April 2009, a serologic examination of her hormone
profile and a transvaginal ultrasound were done on Day 2 of
her spontaneous menstrual cycle. The hormone profile was as
follows: antimu¨llerian hormone, 0.77 ng/mL; follicle-
stimulating hormone, 22.1 mIU/mL; luteinizing hormone,
2.67 mIU/mL; estrogen, 38.1 pg/mL; progesterone, 0.97 ng/
mL. Four antral follicles were observed. Prior to ovulation
stimulation, one shot of gonadotropin-releasing hormone
agonist (Decapeptyl, Ferring Pharmaceuticals, Taiwan) per
day was administered on Day 2 for 4 days in addition to
a recombinant human growth hormone (Saizen, Merck
Serono, Taiwan) on Day 3 for 3 days to induce endogenous
hormone release. Ovulation stimulation started on Day 5 by
daily injection of menotropin (Menopur, Ferring Pharma-
ceuticals, Taiwan) 225 IU for 2 days followed by 75 IU until
the day of ovulation triggering. As one follicle reached the
diameter of 1.7 mm, human chorionic gonadotropin (hCG)
was injected. Transvaginal ultrasound-guided oocyte
retrieval was performed approximately 34e35 hours after the
hCG trigger. One oocyte cumulus corona complex was ob-
tained and placed in hyaluronidase 80 mIU/mL for 10e15
seconds. The oocyte was then transferred to regular tissue
culture media for complete removal of the corona cells
within 3 hours by repeated aspiration with a finely pulledcs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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hour later by the Cryotop method (Kitazato Bio-
Pharmaceuticals, Japan).
The second oocyte retrieval was performed in the following
cycle by initiating ovulation stimulation on Day 6 with
clomiphene citrate 100 mg/day for 6 days then with meno-
tropin 150 IU/day on Day 13 until Day 17, the day of the hCG
trigger. Approximately 34e35 hours after that, a transvaginal
ultrasound-guided oocyte retrieval was performed. One oocyte
was harvested and treated within 3 hours after oocyte retrieval.
One matured oocyte was vitrified 1 hour later using the
Cryotop method.
In November 2009, the woman married and wanted to
undergo a natural fresh in vitro fertilization (IVF) cycle. No
oocyte was obtained this time, so she requested a warmed
oocyte-IVF cycle. Two previously gathered vitrified oocytes
were warmed and both survived. Fertilization was achieved
via intracytoplasmic sperm injection with a fresh semen
sample 2 hours postwarming, and after 16e18 hours, two
pronuclei were observed in both zygotes. The zygotes were
then transferred to global media (LifeGlobal, Guilford, CT,
USA) supplemented on Day 1 with 10% Quinns Advantage
serum protein substitute (CooperSurgical, Inc., Trumbull, CT,
USA).
Prior to the embryo transfer, the patient underwent
a cervical bacteria culture, chlamydia and human papilloma-
virus screening tests, and hysteroscopy to evaluate the uterine
cavity. The bacterial and viral tests were negative. The hys-
teroscopy revealed negative abnormal findings in the uterine
cavity with bilateral tubal ostium opening. The endometrial
lining was 8 mm on Day 12 of the cycle, the day of the oocyte
warming. Endometrium preparation began on the same day
with oral progesterone 300 mg/day. Three days later, two
eight-cell embryos were transferred back to the patient’s
womb under transabdominal ultrasound monitoring. We ach-
ieved luteal supplementation through vaginal progesterone
180 mg combined with oral estradiol 5 mg daily. Her Day 7
serum progesterone level was 15.8 ng/mL.
The patient’s serum b-hCG levels were noted at 373.07 mIU/
mL and 1762.73 mIU/mL, respectively, on Days 16 and 19 after
the embryo transfer. Transabdominal ultrasound showed one
viable singleton intrauterine pregnancy at 7 weeks’ gestation.
During her pregnancy, she developed pregnancy-induced
hypertension; however, the situation was well controlled. A
healthy baby girl weighing 2720 g was delivered by cesarean
section after 39 weeks, 2 days’ gestation. At the follow-up at 9
months the baby was developing normally.
This study documents a healthy live birth after oocyte
vitrification. We also demonstrated that fertility could be
reserved in women with DOR through multiple oocyte
retrievalevitrification cycles. This strategy could be applied
not only in women who would like to preserve their fertility,
but also in those who plan to undergo IVF treatment. For
a woman with DOR who is older than 43 years, the pregnancy
and live birth rates might be reduced due to fewer oocytes/
embryos being transferred per IVF-embryo transfer (ET)
cycle. We proposed dividing a traditional IVF-ET treatmentinto two parts. Multiple oocyte retrieval-vitrification cycles to
accumulate oocytes would be performed first. Once a suffi-
cient number of oocytes is reached (depending on the woman’s
age), the second part, warming and the following IVF-ET
procedure, would be completed.
In women treated with warming oocyte-ET, an inverse
correlation is found between the ongoing pregnancy rate and
an age older than 40 years. The cumulative ongoing pregnancy
rate was found to be highest when the woman is 34 years of
age or younger [17]. According to the prospective controlled
study of Kim et al [7], in young and fertile women who
underwent IVF cycles, a high pregnancy rate and live birth rate
was maintained after 6 months of oocyte vitrification. This
result hinted that if single women of reproductive age could
preserve their oocytes as early as possible, they could then
determine for themselves in the future when they are ready for
marriage and childbearing without compromising the preg-
nancy rate.
The clinical outcome in our report suggests that the age
limitation could be overcome by storing vitrified oocytes, thus
making life planning more flexible. The request for fertility
preservation could be viewed as preventive medicine for
infertility and extended to nononcologic applications. The
proposed oocyte “self-cryobanking” could benefit women of
reproductive age by preserving their reproductive potential. As
time passes, this concept is becoming more popular and
gradually more acceptable.References
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